All feline diagnoses

Your cat was diagnosed with Nasal Planum Squamous Cell Carcinoma (Solar-Induced). Solar-induced SCC. White or light-pigmented cats predisposed. UV exposure is primary risk factor. Better prognosis than oral SCC. Progression from actinic keratosis to carcinoma in situ to invasive SCC. Compare 5 treatment options for cats including Nosectomy (Surgical Excision), Accelerated External Beam RT (1-Week Protocol), HDR Brachytherapy — with survival times, costs, and what to expect during treatment.

🐈

Nasal Planum Squamous Cell Carcinoma (Solar-Induced)

variable (T1-T4)

BreedsWhite catsLight-pigmented cats
feline

Epithelial

About This Cancer

Nasal planum squamous cell carcinoma arises from the skin covering the nose (the nasal planum) in cats. It is primarily caused by chronic ultraviolet radiation exposure, and white or lightly pigmented cats are at dramatically higher risk — essentially, this is a sun-induced skin cancer analogous to certain forms in humans. The disease typically progresses through a recognisable sequence: initially, the nose develops redness and crusting (actinic keratosis), which advances to carcinoma in situ (abnormal cells confined to the surface), and eventually to invasive squamous cell carcinoma. Early-stage disease responds well to several treatments including surgery (nosectomy), radiation therapy, and cryotherapy. The prognosis is significantly better than for oral SCC in cats, with cure possible when the disease is caught before deep invasion.

Practical T-Staging for Feline Nasal Planum SCC

Clinical staging based on tumour size, depth of invasion, and local extent. No universally standardised system; this represents consensus clinical practice.

Stage T1 (Superficial)Superficial, non-invasive lesion confined to epithelium. <2cm. Amenable to cryotherapy, plesiotherapy, or conservative surgery.
Stage T2 (Locally invasive)Invasion into dermis/subcutis. 2-4cm. Suitable for nosectomy or definitive RT.
Stage T3 (Advanced local)Invasion beyond nasal planum into nasal cavity or adjacent structures. >4cm. Requires aggressive surgery or RT.
Stage T4 (Extensive)Extensive local invasion into bone, orbit, or deep nasal structures. Poor surgical candidacy. RT or palliation.
Prognostic Factors(2)
T stageT1-T2 (superficial) carry better prognosis than T3-T4 (deep invasion)
Bone involvementDeep bone invasion worsens prognosis and limits surgical options
Minimum Workup(5 steps)
1Biopsy with histopathology (confirm invasive SCC vs actinic keratosis/CIS)
2CT of nasal region if considering surgery (assess bone involvement)
3Thoracic radiographs
4Regional lymph node assessment
5CBC, chemistry panel

Median Survival Time Comparison

How long the average patient survives with each treatment

Bar opacity reflects evidence strength
Nosectomy (Surgical Excision)
~20 mo
Accelerated External Beam RT (1-Week Protocol)
~30 mo
HDR Brachytherapy
~28 mo
Cryotherapy
~8 mo
Strontium-90 Plesiotherapy
See notes
Reading this page: MST (Median Survival Time) is how long the average patient survives with a given treatment. ORR (Overall Response Rate) is the percentage of patients whose tumour shrank or disappeared. CR = Complete Response (tumour gone); PR = Partial Response (tumour shrank). Hover over any abbreviation for a quick explanation.
Strength of Evidence

Each treatment is rated by how much published research supports its use. Solid bars indicate stronger evidence; dashed bars mean less certainty.

StrongLarge published studies with strong agreement among veterinary oncologists.
ModerateWidely used in clinical practice, but supported by smaller or retrospective studies.
IndirectEvidence comes from a different tumour type or species and has been applied here.
LimitedVery little published data is available for this specific treatment.

Please note: All treatment data is sourced from published peer-reviewed literature. Survival times and cost figures are approximate guides. Your pet's individual factors — including tumour grade, stage, and overall health — will influence outcomes and should guide all treatment decisions. The strength-of-evidence rating reflects how much research exists, not how strongly a treatment is recommended. This tool is designed to help you have informed conversations with your veterinary oncologist, not to replace them. Costs shown are US referral centre estimates and may vary significantly by region.